Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer

Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of a humanized anti-Trop-2 IgG antibody conjugated via a hydrolysable linker to SN-38, the topoisomerase I-inhibitory active component of irinotecan. We investigated whether Trop-2-expression and homologous recombination repair (HRR)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Cardillo, Thomas M., Rossi, Diane L., Zalath, Maria B., Liu, Donglin, Arrojo, Roberto, Sharkey, Robert M., Chang, Chien-Hsing, Goldenberg, David M.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2020
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7597411/
https://ncbi.nlm.nih.gov/pubmed/33196706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27766
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires